Coronary heart disease risk assessment in HIV-infected patients: A comparison of Framingham, PROCAM and SCORE risk assessment functions

International Journal of Clinical Practice

Volumn 64, Issue 6, 2010, Pages 739-745

  Moreira Guimaraes M M ^a   Bartolomeu Greco, D ^a   Ingles Garces, A H ^a   De Oliveira Jr , A R ^a   Bastos Foscolo R ^a   De Campos MacHado, L J ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; FEMALE; FRAMINGHAM EQUATION; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE CARDIOVASCULAR MUNSTER SCORING; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SYSTEMIC CORONARY RISK EVALUATION; TREATMENT DURATION;

ADULT; AGED; ANTI-HIV AGENTS; CORONARY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; YOUNG ADULT;

EID: 77950660203     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02248.x     Document Type: Article

References (33)

1. Hogg RS, O'Shaughnessy MV, Gataric N et al. Decline in deaths from Aids due to new antiretrovirals. Lancet 1997 349 : 1294.
2. Palella FJ Jr., Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998 338 : 853 860.
3. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998 352 : 1725 1730.
4. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000 356 : 1423 1430.
5. Guimarães MM, de Oliveira AR Jr., Penido MG et al. Ultrasonographic measurement of intra-abdominal fat thickness in HIV-infected patients treated or not with antiretroviral drugs and its correlation to lipid and glycemic profiles. Ann Nutr Metab 2007 51 : 35 41.
6. Guimarães MM, Greco DB, Figueiredo SM et al. High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection. Atherosclerosis 2008 201 : 434 439.
7. Depairon M, Chesex S, Sudre P et al. Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy. AIDS 2001 15 : 329 334.
8. Meng Q, Lima JAC, Lai H et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J 2002 144 : 642 648.
9. Manguili A, Gerrior J, Tang AM et al. Risk of cardiovascular disease in a cohort of HIV-infected adults: a study using carotid intima-media thickness and coronary artery calcium score. Clin Infect Dis 2006 43 : 1482 1489.
10. Torriani FJ, Komarow L, Parker RA et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol 2008 52 : 569 576.
11. Grunfeld C, Delaney JAC, Wanke C et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009 23 : 1841 1849.
12. Dubé MP, Stein JH, Aberg JA et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003 37 : 613 627.
13. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001 285 : 2486 2497.
14. Anderson KM, Wilson PW, Odell PM et al. An updated coronary risk profile. A statement for health professionals. Circulation 1991 83 : 356 362.
15. Haq IU, Jackson PR, Yeo WW et al. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995 346 : 1467 1471.
16. Wilson PW, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998 97 : 1837 1847.
17. Menotti A, Lanti M. Comparison of the Framingham risk function-based coronary chart with risk function from an Italian population study. Eur Heart J 2000 21 : 365 370. (Pubitemid 30107553)
18. De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and invited experts). Atherosclerosis 2004 173 : 381 391.
19. Assmann G. Lipid Metabolism Disorders and Coronary Heart Disease: Primary Prevention, Diagnosis, and Therapy Guidelines for General Practice, 2nd edn.
20. Knobel H, Jericó C, Montero M et al. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDs 2007 21 : 452 457.
21. González C, Rodilla E, Costa JA et al. Cardiovascular risk by Framingham and SCORE in patients 40-65 years old. Med Clin (Barc) 2006 126 : 527 531.
22. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Münster (PROCAM) study. Circulation 2002 105 : 310 315. (Pubitemid 34106178)
23. Landis JR, Kock CG. The measurement of observer agreement for categorical data. Biometrics 1977 33 : 159 174.
24. Law MG, Friis-Møller N, El-Sadr WM, et al. The use of Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006 7 : 218 230.
25. Hadigan C, Meigs JB, Wilson PW et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis 2003 36 : 909 916. (Pubitemid 36403525)
26. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999 353 : 2093 2099. (Pubitemid 29278477)
27. Savès M, Chêne G, Ducimetière P et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis 2003 37 : 292 298. (Pubitemid 36930361)
28. Game FL, Jones AF. Coronary heart disease risk assessment in diabetes mellitus - a comparison of PROCAM and Framingham risk assessment functions. Diabet Med 2001 18 : 355 359. (Pubitemid 32679382)
29. Friis-Møller N, Thiébaut R, Reiss P et al. Predicting the risk of coronary heart disease in HIV-infected patients: the D:A:D risk equation. Program and Abstracts of the 14 th Conference on Retroviruses and Opportunistic Infections, February 25-28, 2007
30. Marrugat J, Subirana I, Comín E et al. Validity of na adaptation of the Framingham cardiovascular risk function: the VERIFICA study. I Epidemiol Community Health 2007 61 : 40 7. (Pubitemid 46114588)
31. Mostaza JM, Vincente I, Tabeada M et al. La aplicación de las tables del SCORE a varones de edad avanzada triplica el numero de sujetos clasificados de alto riesgo en compaación la función de Framingham. Med Clin 2005 124 : 487 490.
32. Vrentzos GE, Papadakis JA, Ganotaki ES et al. Predicting coronary heart disease risk using the Framingham and PROCAM equations in dyslipidaemic patients without overt vascular disease. Int J Clin Pract 2007 61 : 1643 1653.
33. Reynolds TM, Twomey PJ, Wierzbicki AS. Coronary evaluation of coronary risk scores: implications for cardiovascular risk screening. Curr Med Res Opin 2004 20 : 811 818.